You have a formula, packaging samples, and a factory ready to run production. The supplier sends over an ISO certificate, a certificate of analysis, and an FDA facility number. Great. So, is the brand covered under MoCRA?
Maybe. But those three documents do not answer the whole question.
The Modernization of Cosmetics Regulation Act of 2022, better known as MoCRA, splits duties across the company named on the label, the manufacturing facility, and sometimes a U.S. agent. A factory can support much of the work. It cannot magically absorb every duty just because it made the product.
This guide maps the roles and documents for private label beard care, hair styling, shaving, skincare, body care, deodorant, and fragrance products sold in the United States. It is written for buyers, brand owners, importers, and product teams—not only regulatory specialists.
It is educational information, not legal advice. Product classification and company structure can change the answer, so involve qualified U.S. regulatory counsel when the facts are unclear.
What MoCRA Changed for Private Label Men’s Grooming
MoCRA is the largest expansion of FDA’s cosmetics authority since 1938. It introduced or strengthened requirements around facility registration, cosmetic product listing, safety substantiation, adverse-event reporting, records access, recall authority, and label contact information. The FDA’s MoCRA overview is the best starting point for the official framework.
It can cover everyday beard, hair, facial, shaving, body-care, deodorant, and fragrance products when marketed as cosmetics. Ingredients, claims, intended use, and consumer expectations may move a product into another regulatory category. This is where a harmless-looking marketing sentence can create a large compliance detour.
MoCRA also does not turn ordinary cosmetics into pre-approved products. FDA generally does not approve a standard cosmetic formula before sale. Registration and listing are not product approval, either. Think of them as entries in FDA’s operating map, not a gold medal from the agency.
The scale of that map is already substantial. FDA reported 16,398 active cosmetic facility registrations and 1,298,361 active cosmetic product listings as of June 30, 2026 on its registration and listing portal. Those figures will change, but they show that listing is now normal operating work, not an edge case.
Classify the Product Before You Divide the MoCRA Work
Do not begin with the filing form. Begin with the product and its claims.
A beard oil promoted to soften facial hair, improve shine, and condition the skin is generally in cosmetic territory. A pomade promising texture and hold is also a familiar cosmetic. So are a face cleanser, a scented aftershave, and a body lotion sold to moisturize dry-feeling skin.
The lane can change when a claim says the product treats disease or affects the body’s structure or function. FDA’s guide on whether a product is a cosmetic, a drug, or both gives clear examples.
| Marketing direction | Likely regulatory concern | Men’s grooming example |
| Cleanses, perfumes, moisturizes, conditions, or changes appearance | Usually cosmetic territory | “Adds texture and a matte finish” |
| Restores hair growth or changes a body function | Drug claim risk | “Regrows thinning hair” |
| Treats or prevents dandruff | Cosmetic/drug combination | “Controls dandruff” shampoo |
| Treats acne, eczema, folliculitis, or infection | Drug claim risk | “Treats razor-bump inflammation” |
| Provides SPF or prevents sunburn | Cosmetic/drug combination | Moisturizer with SPF claims |
| Reduces perspiration | Cosmetic/drug combination | Antiperspirant deodorant |
Words such as “anti-inflammatory,” “heals,” and “antifungal” also deserve review. Ads and marketplace copy may help establish intended use, so packaging, web copy, and influencer instructions should tell the same regulatory story. If a brand turns an ordinary shampoo into an anti-dandruff product through claims, a cosmetics-only plan is no longer enough.
The MoCRA Role Map: Who Owns What?
Here is the short version: the factory usually owns facility-level work, while the label-named responsible person owns product and post-market duties. Yet “usually” needs some unpacking.
The responsible person
Under MoCRA, the responsible person is the manufacturer, packer, or distributor whose name appears on the cosmetic product label under the relevant labeling law.
In a common private label setup, a Chinese contract manufacturer makes the beard oil, but the U.S. brand or distributor is named on the bottle. That label-named company will often be the responsible person. It should be ready to ensure the product is listed, maintain adequate safety substantiation, receive complaints, report serious adverse events, and keep required records.
“Our manufacturer handles FDA” is too fuzzy. Handles which task, for which entity, using whose account?
The facility owner or operator
A covered facility that manufactures or processes cosmetics for U.S. distribution must be registered with FDA and renew its registration every two years. A foreign factory is not excused because it sits outside the United States.
One facility needs one registration even if it serves many brands. An authorized responsible person may submit it, but the parties should document who controls updates.
The distinction is simple enough: facility registration describes where covered manufacturing or processing occurs; product listing describes what cosmetic product is marketed. One does not replace the other.
The foreign facility’s U.S. agent
A foreign cosmetic facility registration must identify a U.S. agent. This person or company acts as FDA’s communication contact for the foreign facility.
The U.S. agent is not automatically the label-named responsible person, importer of record, listing owner, or consumer complaint contact. One company might accept several roles, but that must be deliberate.
Importers, distributors, retailers, and fulfillment providers
Holding inventory does not by itself make a warehouse the responsible person. A distributor can become the responsible person when its name appears on the label in the relevant capacity. An importer may also have contract, customs, marketplace, or insurance duties that sit beside MoCRA.
Your agreement should reflect the real supply chain. If a distributor is placed on the label but refuses to own complaints or listings, there is a gap before the first unit ships.
A practical RACI matrix
The table below is a sensible starting model, not a substitute for reviewing the actual label and contracts.
| Activity | Brand / responsible person | Contract manufacturer | Laboratory / safety expert | Foreign facility U.S. agent | Importer / distributor |
| Product classification and claims | Accountable | Consulted | Consulted | Informed | Consulted |
| FEI and facility data | Informed | Accountable | — | Consulted | Informed |
| Facility registration and renewal | Ensure it is complete | Responsible / accountable | — | Supports FDA communication | Informed |
| Cosmetic product listing | Accountable | Supplies data or submits if authorized | — | — | May be responsible if named on label |
| Safety substantiation | Accountable | Supplies formula and manufacturing evidence | Evaluates evidence and gaps | — | Informed |
| Batch manufacturing and release | Informed | Accountable | Performs agreed testing | — | Informed |
| Complaint intake and triage | Accountable | Investigates product/batch issues | Supports medical or technical review | — | Routes reports promptly |
| Serious adverse-event report | Accountable | Supports investigation | Consulted | — | Routes information immediately |
| Formula, artwork, or facility changes | Approves and updates records | Notifies before change | Reassesses when needed | Updates facility contact data where relevant | Informed |
| Recall and traceability support | Accountable for brand response | Provides batch and distribution evidence | Supports investigation | Supports FDA contact if facility-related | Provides customer/distribution records |
A contract can assign the labor. It cannot make statutory accountability disappear.
The MoCRA Document Pack to Build Before the First Purchase Order
MoCRA readiness is not a single certificate. It is a connected file that ties the marketed product to its formula, label, factory, safety evidence, and post-market process.
1. Role and filing records
Start with a one-page responsibility memo. Record the label-named legal entity, responsible person, every manufacturing or processing site, facility address and FEI, registration status, U.S. agent, product-listing owner, update owner, and storage location for confirmations.
Do not accept a screenshot with no matching legal entity or facility address. The identifiers must point to the actual site performing covered work.
FDA’s final registration and listing guidance also explains a useful contract-manufacturing detail: a responsible person can submit or ensure submission of the product listing, and only one registration is required for a facility serving multiple responsible persons.
2. Formula and raw-material records
The formula file is the spine of the technical package. It should connect to the exact production version, not a pretty sample from six months ago.
Keep the controlled formula number and revision, full composition for the qualified safety reviewer, label INCI declaration, raw-material specifications, supplier identities, relevant fragrance/allergen or impurity data, color-additive review, product-contact packaging, and change history.
Confidentiality is a real commercial concern. A manufacturer may not want to email an unrestricted quantitative formula to several people. Fine. The contract can allow controlled access by a qualified assessor, regulator, insurer, or agreed third party. “Confidential” cannot mean that nobody responsible for safety can ever review the evidence.
3. Safety substantiation
The responsible person must ensure and maintain records supporting adequate safety substantiation. MoCRA does not prescribe one universal test list for every cosmetic. That is helpful, but it also means a brand needs a reasoned plan.
Depending on formula, packaging, users, and use pattern, the file may draw from ingredient toxicology, supplier data, impurity limits, stability, packaging compatibility, microbiological quality, preservative-effectiveness testing, relevant irritation or sensitization work, exposure, warnings, and qualified expert review.
A certificate of analysis confirms that a batch met selected specifications. It does not automatically prove that the product is safe under labeled or customary use. A COA is one tile in the floor, not the whole floor.
For a broader view of product-development due diligence, see BunJoin’s private label men’s grooming manufacturer guide.
4. Manufacturing and release records
The manufacturing package should trace a lot from raw materials through shipment. Keep approved manufacturing instructions, executed batch records, lot traceability, in-process controls, finished-product specifications, COAs, relevant microbiological results, packaging checks, deviations, retention samples, release authorization, and shipment records.
ISO 22716 can be useful evidence of a cosmetic GMP system, but it is not FDA approval and not a product-specific MoCRA certificate. As of August 2, 2026, FDA still describes its cosmetic GMP materials as guidance while the final MoCRA GMP regulation remains pending. Its current cosmetic GMP inspection checklist is useful context, but brands should recheck the rulemaking status before publication or launch.
5. Label, claims, and post-market records
Keep the final approved label artwork with its revision date. The review should cover the statement of identity, net quantity, ingredient declaration, name and place of business, required warnings, and other applicable U.S. labeling rules.
MoCRA also requires a domestic address, domestic telephone number, or electronic contact information through which the responsible person can receive adverse-event reports. That contact channel should work. A dead inbox printed on 30,000 bottles is, well, not a system.
Pair the artwork with claims evidence, website and marketplace review, a complaint SOP and intake form, a seriousness/escalation decision tree, technical contacts, an investigation template, distribution records, and recall contacts.
The responsible person must report a serious adverse event associated with a cosmetic used in the United States to FDA within 15 business days and include a copy of the retail label. New medical or other information received within one year of the initial report must also be sent within 15 business days. FDA’s serious adverse-event reporting instructions explain the process.
Adverse-event records generally must be kept for six years. A qualifying small business may have a three-year period. The statutory topics—adverse events, GMP, listing, safety substantiation, labeling, records, recalls, and small-business provisions—are organized in Chapter VI of the FD&C Act.
A Practical Workflow from China OEM/ODM to U.S. Launch
A reliable men’s grooming product development partner should help make the evidence trail easier to manage. Still, the brand needs clear approval gates.
Gate 1: Lock the product and claims brief
Define the product, users, body area, directions, warnings, and claims. Screen cosmetic-versus-drug status before artwork. A matte styling powder can promise texture and finish; restoring lost hair is a different regulatory route. BunJoin’s private label men’s hair styling OEM/ODM guide adds product-format context.
Gate 2: Verify the supplier and every facility
Record which site compounds, fills, packs, labels, or processes the product. Confirm legal names, FEIs, registration ownership, U.S. agents, and subcontractors. Ask whether any step may move after sample approval.
Gate 3: Lock the formula, packaging, and safety plan
Freeze the formula and packaging. Agree on specifications and risk-based testing. Give the safety reviewer enough data to assess the marketed product.
Gate 4: Lock the label and listing data
Confirm the label-named company and contact channel. Prepare the product category, responsible-person details, facility registration numbers, ingredient list, and other listing fields. Product listings receive annual updates; facility registration is renewed biennially.
Gate 5: Produce, release, and transfer the file
Release against approved specifications. Transfer the COA, batch identity, date information, shipment records, listing confirmation, and artwork version.
Gate 6: Operate the post-market system
Test the complaint route before launch. Can customer service identify a possible serious event, the factory locate the lot, and the team assemble a report inside 15 business days?
This is also where supplier culture matters. BunJoin explains more about its sourcing and development approach on the About BunJoin page.
Five Private Label Scenarios That Change the Paperwork
1. A U.S. brand is named on the label; a Chinese factory makes the product
The brand is often the responsible person. The factory supports facility registration; the brand ensures listing and controls safety and post-market records. The foreign facility needs a U.S. agent.
2. A U.S. distributor is named on the label
The distributor may be the responsible person. Listing control, safety-file access, complaints, and reporting must match the label and contract.
3. One brand uses two factories
Each covered facility needs the appropriate registration. Keep SKU-to-site traceability; a backup factory is not merely a purchasing detail.
4. One formula has several scents, sizes, or kits
Certain products with identical formulas, or formulas differing only in specified ways, may be submitted together under current guidance. Keep a SKU-to-formula matrix. A beard set also needs component-level clarity; see building a complete private label beard care system.
5. The brand believes it is a small business
Qualifying small businesses may be exempt from certain GMP, registration, and listing rules based on inflation-adjusted U.S. cosmetic sales. Exceptions cover specified higher-risk categories, including eye-mucous-membrane contact, injected or internal-use products, and certain products altering appearance for more than 24 hours. This is not an exemption from safety, labeling, claims, adulteration, or misbranding rules.
Contract Clauses That Keep the Compliance File Usable
The agreement should cover controlled access to formula and safety evidence; advance approval of formula, supplier, packaging, facility, or subcontractor changes; facility and U.S.-agent maintenance; listing support; traceability; retention samples; audits; recalls; and document retention. Set measurable complaint and serious-event response times. “Promptly” is a slippery word when the FDA clock is running.
Common MoCRA Mistakes in Men’s Grooming Launches
| Mistake | Why it fails |
| Treating facility registration as product listing | They are separate submissions |
| Calling the U.S. agent the responsible person | One is a foreign-facility contact; the other is tied to the label |
| Advertising “FDA approved” or “MoCRA certified” | Registration and listing are not approval programs |
| Calling a COA the safety file | Passing batch specifications is not a complete safety rationale |
| Quietly changing fragrance or preservative | Safety, stability, INCI, artwork, and listing data may change |
| Using hair-growth, acne, or dandruff treatment copy | Claims may move the product into drug regulation |
| Assuming small-business status covers everything | Only specified provisions are affected |
A 30-Day MoCRA Readiness Plan
Days 1–5: List every U.S. SKU. Classify each product and review its claims. Identify the company named on each label.
Days 6–10: Map all manufacturing and processing facilities. Verify FEIs, registration status, U.S. agents, and renewal ownership.
Days 11–18: Audit formulas, raw-material records, safety substantiation, specifications, labels, and claims evidence. Build a gap list with named owners.
Days 19–24: Confirm product listings, filing access, annual updates, change control, and contract duties.
Days 25–30: Run a mock complaint, serious adverse event, lot-trace, and recall exercise. Fix slow handoffs before consumers find them for you.
If you are planning a new U.S. men’s grooming line, you can discuss your launch documents with BunJoin. The useful conversation is not “Can you give me a compliance badge?” It is “Can we show who owns every task and produce the evidence for this exact SKU?”
Conclusion
MoCRA readiness is an operating system, not a framed certificate.
The label helps determine the responsible person. The physical manufacturing activity determines which facilities may need registration. The product formula, use, and claims determine the regulatory lane. Then the documents connect those facts: formula records, safety substantiation, specifications, batch files, label approvals, listings, complaints, and adverse-event procedures.
A capable OEM/ODM partner can supply much of the technical evidence and perform agreed filings. The brand still needs visibility, access, and clear written responsibilities. Get that structure in place before the first purchase order. It is much cheaper than relabeling inventory—or trying to build a safety file during a complaint investigation.
FAQs
1. Who is the responsible person for a private label cosmetic under MoCRA?
It is the manufacturer, packer, or distributor whose name appears on the cosmetic label under the relevant U.S. labeling provisions. In many private label arrangements, that is the brand owner or distributor shown on the packaging, not the contract factory.
2. Is the responsible person the same as the U.S. agent?
No. A foreign facility’s U.S. agent is FDA’s contact for that facility. The responsible person is tied to the company named on the product label. One service provider may accept both roles, but they remain different functions.
3. Does my manufacturer’s FDA facility registration cover my brand?
It may cover the facility-registration side for the site making your product. It does not automatically complete your cosmetic product listing or the responsible person’s safety, labeling, complaint, and adverse-event duties.
4. Who submits the cosmetic product listing—the brand or the factory?
The responsible person must submit the listing or ensure it is submitted. A manufacturer or service provider may do the filing when authorized. The agreement should say who submits, who owns account access, and who handles annual updates and changes.
5. What documents should a private label men’s grooming manufacturer provide?
At minimum, request facility and product data, controlled formula information, INCI, raw-material and finished-product specifications, appropriate safety and test evidence, batch records, COAs, traceability, approved packaging information, and change notifications. The exact package depends on product risk and use.
6. Is a COA enough for MoCRA safety substantiation?
Usually not by itself. A COA shows selected batch results against specifications. Safety substantiation considers ingredients, exposure, intended use, packaging, microbiological risk, available studies, and other relevant evidence. A qualified safety review may identify additional needs.
7. Are small men’s grooming brands exempt from MoCRA?
Some qualifying small businesses are exempt from certain GMP, facility-registration, and product-listing provisions, subject to an inflation-adjusted sales test and product exceptions. They are not exempt from the basic duty to market safe, properly labeled, non-adulterated, and non-misbranded cosmetics.
8. Do beard oils, pomades, and aftershaves need FDA approval?
Ordinary cosmetics generally do not need FDA premarket approval, except that color additives must be authorized for their intended use. The products still need to comply with applicable safety, labeling, listing, and other legal requirements. Drug claims can change the pathway.
9. When does a men’s grooming product become an OTC drug?
It may be a drug, or both a cosmetic and a drug, when its intended use includes treating or preventing disease or affecting body structure or function. Common examples include hair-growth, anti-dandruff, acne-treatment, SPF, and antiperspirant claims.
10. What happens when the formula, fragrance, label, or factory changes
Run the change through a written review. Check safety substantiation, stability, specifications, ingredients, claims, artwork, facility data, product-listing information, and existing inventory. Approve the change before production rather than trying to reconstruct it later.
